UK’s MHRA issues hydrochlorothiazide safety update

Organisation: Position: Deadline Date: Location:

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update: Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use.

The update says: “Advise patients taking hydrochlorothiazide-containing products of the cumulative, dose-dependent risk of non-melanoma skin cancer, particularly in long-term use, and the need to regularly check for (and report) any suspicious skin lesions or moles. Counsel patients to limit exposure to sunlight and UV rays and to use adequate sun protection.

“Further details of the drug safety update, which includes advice for healthcare professionals, and a letter about the risk and advice sent to prescribers and dispensers of hydrochlorothiazide-containing medicinal products, are available on the MHRA website.”

RPharms material
Medicines and Healthcare Products Regulatory Agency material


Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.